- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
BD, Mitsubishi Gas Chemical ink pact to explore ways to advance biologic drug delivery
MGC has developed the OXYCAPT multilayer structure applied on silicon free plastic syringe barrels to provide high breakage resistance, oxygen and vapor barrier, low protein adsorption, very low extractables, high UV barrier and pH stability.
Franklin Lakes: BD (Becton, Dickinson and Company), a global medical technology company, and Mitsubishi Gas Chemical Company, Inc., a R&D-oriented chemical manufacturer based in Tokyo, Japan, have announced that they have entered into an agreement to investigate further development of OXYCAPT - an innovation from MGC that integrates the best of plastic and glass for plastic syringes.
Together, the companies will look into applying the OXYCAPT technology to the next generation of prefillable syringes (PFS) for advanced biologic pharmaceuticals.
"The biopharmaceutical industry continues to rely on PFS for the effective, reliable and consistent administration of medications," said Bruno Baney, Vice President, R&D BD Medical – Pharmaceutical Systems. "As our customers continue to grow their drug pipelines we are constantly exploring solutions to deliver newer compounds in robust, stable, and ready-to-administer formats. This agreement will further help us do so – as MGC's experience in providing technical innovation in materials will serve as a strategic complement to our legacy of supporting the latest innovations in drug delivery for our customers."
MGC has developed the OXYCAPT multilayer structure applied on silicon free plastic syringe barrels to provide high breakage resistance, oxygen and vapor barrier, low protein adsorption, very low extractables, high UV barrier and pH stability.
"Since launching OXYCAPT, more and more pharmaceutical companies have been interested in applying it to their biologics or regenerative medicines such as gene/cell therapies", said Ko Kedo, an executive officer of R&D division. "As we have looked for a strategic partner to enhance presence of OXYCAPT in the pharmaceutical industry, the partnership with BD will be an ideal solution for MGC. We believe this agreement will make it possible for customers to choose the best syringes for their drugs."
Some pharmaceutical compounds based on technologies such as mRNA, viral vectors, or innovative antibodies may face specific stability or integration with device challenges when packaged and administered in glass PFS.
Through this partnership, BD and MGC will explore practical solutions for delivering newer biologic compounds. Both companies share a commitment to advancing sustainability and reducing carbon footprint.
Read also: Reckitt Benckiser cranks up operations to put baby formula on US shelves
Ruchika Sharma joined Medical Dialogue as an Correspondent for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751